Bryan Walker, MHS, PA-C

Advice and resources for colleagues, including community practitioners and neurologists, to encourage collaboration and best support for patients with multiple sclerosis (MS).

An optimistic look at the future management of multiple sclerosis (MS) based on newer treatment options and ongoing research in the field.

Recommendations surrounding the use of complementary and natural therapies to manage symptoms of multiple sclerosis (MS).

Best practices for establishing treatment plans for patients with relapse-remitting multiple sclerosis (RRMS) and making decisions to switch therapies based on inadequate treatment responses, relapse, or disease progression.

An overview of fumarates available as treatment for relapsing multiple sclerosis and recommendations for counseling and caring for patients on these therapies.

Considerations for using anti-CD20 therapies versus other available treatment options for relapsing multiple sclerosis.

An overview of clinical trial data supporting the use of ocrelizumab and ofatumumab as treatment options for patients with relapsing multiple sclerosis.

Variables that impact which S1P receptor modulator is selected as treatment for relapsing multiple sclerosis.

Bryan Walker, MHS, PA-C, describes the rationale for treating relapsing multiple sclerosis (MS) with sphingosine 1-phosphate (S1P1) receptor modulators and compares available options.

Best practices for treating patients with relapsing multiple sclerosis (MS) with cladribine, based on data revealed by clinical trials and experience in real-world practice.

A discussion on the integration of newer therapies, like cladribine, into the treatment landscape for relapsing multiple sclerosis (MS), and insight regarding what is currently understood about risks of disease progression and relapse.

An overview of clinical trial data supporting the use of cladribine as treatment for relapsing multiple sclerosis (MS).

Health care professionals who work in the field of neurology comment on their experience using interferon therapies and glatiramer acetate as treatment for relapsing multiple sclerosis.

The rationale for early treatment of multiple sclerosis, and an overview of limitations that impact the management of relapsing multiple sclerosis.

Important insight related to individualized treatment approaches for patients with relapsing multiple sclerosis.

An overview of revisions to the McDonald criteria used to help diagnose relapsing multiple sclerosis, and recommendations to follow when referring to criteria and imaging results when evaluating patients.